Summary sheet
AMW is a pharmaceutical company specialized in the development and manufacturing of innovative drug delivery systems, i.e. technologies aimed at the targeted delivery and controlled release of pharmaceutical compounds in order to improve their efficacy, safety and convenience. The company has a broad and diversified development pipeline, focused on providing solutions in strongly growing indications such as oncology, neurology, pain therapy and dermatology, which is expected to drive significant revenue growth in the future.
The project will cover the company's substantial Research & Development (R&D) expenses relating to the development of existing and new products It will also include an additional R&D facility and purpose-built manufacturing technologies for innovative drug delivery systems together with associated laboratory and manufacturing equipment.
The promoter's investments concern research, development and innovation activities that will be mainly carried out in existing facilities already authorised for similar activities and volumes and as such, do not require an Environmental Impact Assessment (EIA), according to the relevant EU Directives. However the Bank's services will verify during appraisal whether an EIA is required, as well as the screening decision of the competent authority.
The promoter is a private company not operating in the utilities sector and not having a status of a contracting authority. Thus, it is not covered by the EU directives on procurement.
Loan foreseen under the European Fund for Strategic Investments (EFSI).
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).
Documents
News & Stories
General enquiries and comments
The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.
Media enquiries
Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.
Complaints mechanism
Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.
Zero tolerance against fraud and corruption
The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.
Related publications